薬剤経済学研究に関する最近の話題 ３．薬剤経済評価のための患者アウトカム評価
スポンサーリンク
概要
- 論文の詳細を見る
With the decline in economic growth and increase in the aging population, rational allocation of medical resources has become more important. To construct more effective and efficient medical systems, health-related quality of life (HRQOL) is used not only for evaluating patients' HRQOL, but also for reflecting people's preference to medical resource allocation. In this review article, first we explain HRQOL, especially for cancer patients. Second we focus on the cost-effectiveness of expensive anti-cancer drugs. In addition, to support decision-making based on economic evaluation, we discuss the threshold of cost-effectiveness analysis; how the criteria on cost-effectiveness should be determined.In the first part of this review article, we explain the concept of HRQOL, which is multi-dimensional, consisting of, for example, physical, mental and social domains. HRQOL is classified into profile and index types. The latter is mainly used for economic evaluation to calculate quality-adjusted life years (QALYs). Cost per QALY is a standard indicator to compare the efficiency of medicine or medical intervention. In the second part, we discuss the cost-effectiveness of expensive anti-cancer drugs called molecular targeting drugs. Some of them have been judged to be not cost-effective by, for example, NICE (The National Institute for Health and Clinical Excellence) in UK and other studies. We discuss how such expensive drugs should be dealt with in the context of public health insurance and taxation. Finally we propose that the threshold of cost-effective analysis should be from JPY 5.0 million to JPY 6.0 million based on our international willingness-to-pay (WTP) survey.
- 一般社団法人 日本臨床薬理学会の論文
一般社団法人 日本臨床薬理学会 | 論文
- 臨床家の立場より : 脳循環代謝改善薬
- 生体肝移植ならびに小腸移植術後のタクロリムス投与方法
- 甲状腺機能低下によりWarfarin効果の減弱がみられた症例
- 治験の品質管理における治験コーデイネーターの役割
- 治験,臨床試験,臨床研究とCRC